Elemental impurities in pharmaceutical products adding fuel to the fire

Area of Science:

• Pharmaceutical Science
• Analytical Chemistry

Background:

• Pharmaceutical impurities, including elemental impurities, can arise during drug development, transport, and storage, posing risks to patient safety.
• Current regulations are shifting from component-based concentration controls to permitted daily exposure (PDE) limits for elemental impurities in finished drug products.
• Manufacturers face uncertainty due to a lack of data on elemental impurity levels in common pharmaceutical excipients.

Purpose of the Study:

• To provide updated information on elemental impurities in pharmaceutical materials.
• To review regulatory aspects concerning elemental impurities in active pharmaceutical ingredients and drug formulations.
• To discuss quantitative analytical methods for quality control of elemental impurities in pharmaceutical products.

Main Methods:

• Literature review and compilation of updated information on elemental impurities.
• Analysis of regulatory changes impacting elemental impurity control.
• Review and discussion of current quantitative analytical techniques for elemental impurity detection and quantification.

Main Results:

• Elemental impurities are unavoidable in pharmaceuticals, even under Good Manufacturing Practices (GMP).
• The transition to PDE-based control presents challenges and uncertainties for drug manufacturers.
• There is a need for accessible data on elemental impurity profiles of pharmaceutical excipients.

Conclusions:

• Effective detection and quantification of elemental impurities are crucial for pharmaceutical safety.
• Understanding and adapting to new regulatory frameworks for elemental impurities is essential for the pharmaceutical industry.
• Quantitative analytical methods play a vital role in ensuring the quality control of elemental impurities in pharmaceutical products.